Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody
Data demonstrate early activity with casdozokitug/atezolizumab/bevacizumab; 38% objective response rate including three complete responses
Data support casdozo as a promising novel immuno-oncology agent with clinical activity in liver cancer that... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 18, 2024 Category: Pharmaceuticals Source Type: clinical trials
Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
Ibezapolstat outperformed vancomycin showing eradication of fecal C. difficile at Day 3 of treatment in 15 of 16 treated patients (94%), versus vancomycin which had eradication of C. difficile in 10 of 14 treated patients (71%).
Ibezapolstat, but... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 17, 2024 Category: Pharmaceuticals Source Type: clinical trials
Atsena Therapeutics Receives Rare Pediatric Disease Designation from FDA for ATSN-101 Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis (LCA1)
Positive 12-month safety and efficacy data from ongoing Phase I/II clinical trial of ATSN-101 to be presented at 47th Annual Macula Society Meeting on February 7, 2024
DURHAM, NC, January 16, 2024– Atsena Therapeutics, a clinical-stage... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 16, 2024 Category: Pharmaceuticals Source Type: clinical trials
NRx Pharmaceuticals, Inc. Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis
NRX-101 has demonstrated potent activity against resistant urinary pathogens upon FDA review
QIDP designation grants Priority Review and an additional 5 years of additional product exclusivity
3 million Americans develop complicated Urinary... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 16, 2024 Category: Pharmaceuticals Source Type: clinical trials
Pleco Therapeutics receives FDA Orphan Drug Designation for PTX-252
Nijmegen, The Netherlands– 16th January 2024– The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Pleco Therapeutics BV’s lead compound, PTX-252 for the treatment of Acute Myeloid Leukaemia (AML).... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 16, 2024 Category: Pharmaceuticals Source Type: clinical trials
New Prostate Cancer Foundation-Funded Research To Speed Up Prostate Cancer Clinical Trials Worldwide
LOS ANGELES, Jan. 11, 2024. New analysis of data published by Susan Halabi, PhD, of Duke University could facilitate approval of new prostate cancer treatments almost two years earlier than the current standard.
The study published online January... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 14, 2024 Category: Pharmaceuticals Source Type: clinical trials
Bayer ’s AskBio initiates Phase II GenePHIT trial in Congestive Heart Failure (CHF)
Berlin, Germany/Research Triangle Park, North Carolina, USA, January 11, 2024– Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, have announced... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 11, 2024 Category: Pharmaceuticals Source Type: clinical trials
Reduced Blood Lead Levels Linked to Lower Blood Pressure in American Indians
Reductions correlated with long-term cardiovascular health improvements in NIH-funded study.
January 11, 2024 -- Researchers have linked a decade-long decline in the blood lead levels of American Indian adults to long-term cardiovascular health... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 11, 2024 Category: Pharmaceuticals Source Type: clinical trials
Open Enrollment Commences for Phase 1b/2 Study Evaluating Ampligen in Combination with Imfinzi for the Treatment of Pancreatic Cancer
OCALA, Fla., Jan. 10, 2024. AIM ImmunoTech Inc. (“AIM” or the“Company”) today announced that enrollment is open at Erasmus Medical Center (“Erasmus MC”) in a Phase 1b/2 clinical trial combining AIM’s... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 10, 2024 Category: Pharmaceuticals Source Type: clinical trials
Reduced Drug Use is a Meaningful Treatment Outcome for People with Stimulant Use Disorders
January 10, 2024 -- Reducing stimulant use was associated with significant improvement in measures of health and recovery among people with stimulant use disorder, even if they did not achieve total abstinence. This finding is according to an... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 10, 2024 Category: Pharmaceuticals Source Type: clinical trials
Marius Pharmaceuticals Announces Pilot Study Exploring the Effect of Its Oral Testosterone Therapy, KYZATREX on Male Fertility
RALEIGH, N.C., Jan. 9, 2024. Marius Pharmaceuticals a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, today announced it has initiated a pilot study to better understand the effect of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 9, 2024 Category: Pharmaceuticals Source Type: clinical trials
A Common Marker of Neurological Diseases May Play Role in Healthy Brains
January 9, 2024 -- Researchers have discovered that a protein called phosphorylatedα-synuclein, which is associated with several neurodegenerative diseases such as Parkinson’s disease and Lewy body dementia, is also involved in the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 9, 2024 Category: Pharmaceuticals Source Type: clinical trials
Bayer Starts Phase II Study NIRVANA to Evaluate Elinzanetant in Women with Sleep Disturbances Associated with Menopause
Berlin, January 8, 2024– Bayer, a global leader in women’s healthcare, announced today the expansion of the clinical development program for the investigational compound elinzanetant. The first study participants were recently enrolled... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 8, 2024 Category: Pharmaceuticals Source Type: clinical trials
Bayer ’s Elinzanetant Meets All Primary and Key Secondary Endpoints in Pivotal OASIS 1 and 2 Phase III Studies
Berlin, January 8, 2024– Bayer today announced positive top-line results of the pivotal Phase III studies OASIS 1 and 2 evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo. Elinzanetant successfully... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 8, 2024 Category: Pharmaceuticals Source Type: clinical trials
Residential Addiction Treatment for Adolescents is Scarce and Expensive
January 8, 2024 -- Access to residential addiction treatment centers caring for U.S. adolescents under 18 years old in the United States is limited and costly, according to a new study supported by the National Institutes of Health. Researchers... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 8, 2024 Category: Pharmaceuticals Source Type: clinical trials
